On 27 June 2016, orphan designation (EU/3/16/1689) was granted by the European Commission to Alacrita LLP, United Kingdom, for teriparatide for the treatment of hypoparathyroidism.
The sponsorship was transferred to Alan Boyd Consultants Ltd, United Kingdom, in October 2018.
The sponsorship was transferred to Boyd Consultants Limited, Ireland, in March 2019
|Disease / condition||
Treatment of hypoparathyroidism
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;